[ADMS] Adamas Pharmaceuticals, Inc.


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 17.42 Change: 0.78 (4.69%)
Ext. hours: Change: 0 (0%)

chart ADMS

Refresh chart

Strongest Trends Summary For ADMS

ADMS is in the long-term up 41% in 3 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Adamas Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems in the United States. The company?s lead product candidate, ADS-5102, is being developed for a complication of Parkinson?s disease, known as levodopa-induced dyskinesia, and as a treatment for chronic behavioral symptoms associated with traumatic brain injury. Its portfolio also includes an NDA-submitted fixed-dose combination product candidate, MDX-8704, which is being co-developed with Forest Laboratories, Inc.; and an approved controlled-release product, Namenda XR. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Emeryville, California.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS-2.84 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -99.1% Sales Growth - Q/Q-99.25% P/E-6.16
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA2.99% ROE3.2% ROI
Current Ratio14.25 Quick Ratio Long Term Debt/Equity Debt Ratio0.06
Gross Margin Operating Margin21.43% Net Profit Margin7.87% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities300 K Cash From Investing Activities-18.45 M Cash From Operating Activities-14.06 M Gross Profit
Net Profit-12.2 M Operating Profit-12.23 M Total Assets147.34 M Total Current Assets115.52 M
Total Current Liabilities8.11 M Total Debt Total Liabilities9.79 M Total Revenue230 K
Technical Data
High 52 week42.65 Low 52 week13.68 Last close24.16 Last change1.6%
RSI32.36 Average true range1.15 Beta1.4 Volume92.31 K
Simple moving average 20 days-7.54% Simple moving average 50 days-9.49% Simple moving average 200 days-16.87%
Performance Data
Performance Week-9.55% Performance Month-6.25% Performance Quart-19.33% Performance Half-36.15%
Performance Year40.71% Performance Year-to-date-28.71% Volatility daily2.85% Volatility weekly6.37%
Volatility monthly13.05% Volatility yearly45.2% Relative Volume208.74% Average Volume562.48 K
New High New Low


2019-03-12 16:05:00 | Adamas Announces New Employment Inducement Grant

2019-03-05 12:40:00 | Why Adamas Pharmaceuticals Shares Are Crashing Today

2019-03-05 07:24:27 | The Daily Biotech Pulse: Novartis Psoriasis Drug Found Superior, Ascendis Offering, Adamas Earnings

2019-03-04 21:51:27 | Edited Transcript of ADMS earnings conference call or presentation 4-Mar-19 9:30pm GMT

2019-03-04 21:34:12 | Adamas Pharmaceuticals Inc ADMS Q4 2018 Earnings Conference Call Transcript

2019-03-04 16:35:42 | Adamas Reports Recent Achievements and Financial Results for the Fourth Quarter and Full-Year 2018

2019-02-26 09:41:02 | Will R&D Focus Fuel DENTSPLY SIRONA's XRAY Earnings in Q4?

2019-02-21 10:31:03 | Adamas Pharmaceuticals ADMS Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

2019-02-20 16:50:00 | Adamas to Present at Two Upcoming Investor Conferences

2019-02-20 16:49:00 | Adamas to Announce Fourth Quarter and Year-End 2018 Financial Results and Host Conference Call on March 4, 2019

2019-02-20 09:32:02 | Tenet Healthcare THC Q4 Earnings: What's in the Offing?

2019-02-20 08:18:01 | Can Segmental Growth Fuel Veeva Systems' VEEV Q4 Earnings?

2019-02-18 08:18:01 | AptarGroup ATR to Report Q4 Earnings: What's in Store?

2019-02-12 14:26:45 | Should You Be Worried About Insider Transactions At Adamas Pharmaceuticals, Inc. NASDAQ:ADMS?

2019-02-08 18:49:24 | Adamas Announces New Employment Inducement Grant

2019-02-07 10:34:03 | Is a Beat in Store for Molina Healthcare MOH Q4 Earnings?

2019-02-07 08:15:00 | Report: Exploring Fundamental Drivers Behind Roku, AECOM, 1-800 FLOWERS.COM, Eldorado Resorts, Haverty Furniture Companies, and Adamas Pharmaceuticals — New Horizons, Emerging Trends, and Upcoming Developments

2019-02-01 11:30:00 | LD Micro Welcomes Nearly 1,000 Companies to the LD Micro Index

2019-01-10 16:30:00 | Adamas Announces New Employment Inducement Grant

2019-01-10 10:49:30 | Here's Why These Small-Cap Pharma Stocks Lost as Much as 45% in December

2019-01-06 11:38:02 | Adamas Provides Preliminary Fourth Quarter and Full-Year 2018 GOCOVRI™ Sales Results and Outlines Key Priorities for 2019

2018-12-19 07:46:41 | The Daily Biotech Pulse: Pfizer-Glaxo Set Up Consumer Health Care Venture, New Patent For Adamas

2018-12-18 16:30:00 | Adamas Announces Issuance of New U.S. Patent Covering GOCOVRI™

2018-12-17 21:43:35 | Is Adamas Pharmaceuticals Inc ADMS A Good Stock To Buy?

2018-12-11 15:29:00 | Why Adamas Pharmaceuticals, Inc. Stock Continued to Slide in November

2018-11-09 13:49:52 | Adamas to Present at Three November Investor Conferences

2018-11-08 08:30:00 | Factors of Influence in 2018, Key Indicators and Opportunity within Apptio, Adamas Pharmaceuticals, NEXEO SOLUTIONS, Computer Programs and, Solaris Oilfield Infrastructure, and SPX — New Research Emphasizes Economic Growth

2018-11-02 20:10:33 | Edited Transcript of ADMS earnings conference call or presentation 1-Nov-18 8:30pm GMT

2018-11-02 11:37:00 | The Probable Reason Why Adamas Pharmaceuticals Inc. Is Down Big Today

2018-11-01 17:52:30 | Adamas: 3Q Earnings Snapshot

2018-11-01 16:01:00 | Adamas Reports Third Quarter 2018 Financial Results

2018-11-01 07:30:40 | The Daily Biotech Pulse: AbbVie's Leukemia Drug Trial Meets Endpoint, Denali Strikes Collaboration Deal

2018-10-26 09:00:00 | Adamas to Announce Third Quarter 2018 Financial Results and Host Conference Call on November 1, 2018

2018-10-24 13:11:40 | China cutting rare earth output, unnerving global manufacturers

2018-10-16 09:15:00 | Consolidated Research: 2018 Summary Expectations for Freightcar America, Star Bulk Carriers, Avis Budget Group, Adamas Pharmaceuticals, Model N, and Amphastar Pharmaceuticals — Fundamental Analysis, Key Performance Indications

2018-10-12 09:00:00 | Why Adamas Pharmaceuticals, Inc. Stock Sank in September

2018-10-08 08:30:00 | Adamas Presents Final Results from the Two-Year, Phase 3 Open-Label Study of GOCOVRI™ in Parkinson’s Disease Patients with Dyskinesia

2018-10-05 17:51:53 | Adamas Announces New Employment Inducement Grant

2018-10-05 13:59:10 | When Can We Expect A Profit From Adamas Pharmaceuticals Inc NASDAQ:ADMS?

2018-10-04 09:00:00 | Adamas Announces Publication of Data Demonstrating Dyskinesia’s Impact on Activities of Daily Living in People with Parkinson’s Disease

2018-09-13 07:33:15 | A Financial Overview of Supernus Pharmaceuticals in September

2018-09-12 16:35:03 | Supernus Pharmaceuticals Garners 89% ‘Buy’ Ratings in September

2018-09-12 16:30:00 | Adamas Announces New Employment Inducement Grant

2018-08-20 08:25:00 | Investor Expectations to Drive Momentum within Mazor Robotics, Kinross Gold, Mimecast, DBV Technologies S.A., Adamas Pharmaceuticals, and Adverum Biotechnologies — Discovering Underlying Factors of Influence

2018-08-08 16:30:00 | Adamas Announces New Employment Inducement Grant

2018-08-03 17:35:12 | Edited Transcript of ADMS earnings conference call or presentation 2-Aug-18 8:30pm GMT

2018-08-03 07:52:00 | The Daily Biotech Pulse: Zafgen Executive Departs; Adamas, Acceleron Accelerate On Earnings

2018-08-02 19:05:11 | Adamas Pharmaceuticals ADMS Reports Q2 Loss, Tops Revenue Estimates

2018-08-02 17:59:25 | Adamas: 2Q Earnings Snapshot

2018-08-02 16:01:00 | Adamas Reports Second Quarter 2018 Financial Results